Market Research Logo

Small-Cell Lung Cancer - Pipeline Review, H1 2015

Small-Cell Lung Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Small-Cell Lung Cancer - Pipeline Review, H1 2015’, provides an overview of the Small-Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Small-Cell Lung Cancer Overview
Therapeutics Development
Pipeline Products for Small-Cell Lung Cancer - Overview
Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis
Small-Cell Lung Cancer - Therapeutics under Development by Companies
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
Small-Cell Lung Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Small-Cell Lung Cancer - Products under Development by Companies
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc.
Alchemia Limited
Amgen Inc.
Aposense Ltd.
Array BioPharma Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Blend Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc.
CellAct Pharma GmbH
Cerulean Pharma, Inc.
Cornerstone Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CytRx Corporation
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoCellular Therapeutics, Ltd.
Immunomedics, Inc.
Inbiopro Solutions Pvt. Ltd.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lindis Biotech GmbH
MabVax Therapeutics Holdings, Inc.
MedImmune, LLC
MEI Pharma, Inc.
Merck & Co., Inc.
Mersana Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
MolMed S.p.A.
Mologen AG
Nektar Therapeutics
Neotropix, Inc.
Nippon Kayaku Co., Ltd.
Novartis AG
Omnitura Therapeutics Inc.
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Onyx Pharmaceuticals, Inc.
Oxford BioTherapeutics Ltd
Pfizer Inc.
Polaris Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Tesaro, Inc.
Vertex Pharmaceuticals Incorporated
Zensun (Shanghai) Sci & Tech Co., Ltd.
ZIOPHARM Oncology, Inc.
Small-Cell Lung Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(irinotecan hydrochloride + cisplatin) - Drug Profile
5B1 - Drug Profile
ABT-737 - Drug Profile
Adva-27a - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
alisertib - Drug Profile
amrubicin hydrochloride - Drug Profile
ATT-11T - Drug Profile
AV-203 - Drug Profile
AZD-2811 - Drug Profile
AZD-3965 - Drug Profile
belinostat - Drug Profile
binimetinib - Drug Profile
BIW-8962 - Drug Profile
BMS-986012 - Drug Profile
BMS-986158 - Drug Profile
BTP-277 - Drug Profile
cabozantinib s-malate - Drug Profile
CAP-7.1 - Drug Profile
carboplatin - Drug Profile
carfilzomib - Drug Profile
Cell Therapy 1 for Oncology - Drug Profile
COTI-2 - Drug Profile
COTI-219 - Drug Profile
COTI-4 - Drug Profile
COTI-58 - Drug Profile
CPI-613 - Drug Profile
CRLX-101 - Drug Profile
CX-01 - Drug Profile
Cyt-PLAT - Drug Profile
durvalumab + tremelimumab - Drug Profile
erismodegib - Drug Profile
etirinotecan pegol - Drug Profile
etoposide phosphate next generation - Drug Profile
ganetespib - Drug Profile
ganitumab - Drug Profile
GSK-2879552 - Drug Profile
HMPL-453 - Drug Profile
IBPM-002BZ - Drug Profile
ICT-109 - Drug Profile
indisulam - Drug Profile
ipilimumab - Drug Profile
irinotecan hydrochloride - Drug Profile
JNJ-42756493 - Drug Profile
KIT-SG3227 - Drug Profile
LOP-628 - Drug Profile
LY-2510924 - Drug Profile
ME-344 - Drug Profile
MGN-1703 - Drug Profile
MK-2206 + selumetinib sulfate - Drug Profile
Monoclonal Antibodies to Inhibit Vasopressin V2 Receptor for Small-Cell Lung Cancer - Drug Profile
MRX-34 - Drug Profile
MX-225 - Drug Profile
NGR-hTNF - Drug Profile
nintedanib - Drug Profile
niraparib - Drug Profile
nivolumab - Drug Profile
NK-012 - Drug Profile
NTX-010 - Drug Profile
olaparib - Drug Profile
OMN-54 - Drug Profile
OSI-930 - Drug Profile
OX-004 - Drug Profile
palifosfamide - Drug Profile
pegargiminase - Drug Profile
pembrolizumab - Drug Profile
PF-4989216 - Drug Profile
Recombinant Peptide to Target EGFR for Oncology - Drug Profile
RG-6016 - Drug Profile
rilotumumab - Drug Profile
roniciclib - Drug Profile
RX-3117 - Drug Profile
sabarubicin - Drug Profile
sacituzumab govitecan - Drug Profile
SC-16LD6.5 - Drug Profile
selinexor - Drug Profile
Small Molecules for Small Cell Lung Cancer - Drug Profile
Small Molecules to Inhibit EZH2-EED for Cancer - Drug Profile
solitomab - Drug Profile
STA-128666 - Drug Profile
STA-129183 - Drug Profile
taladegib - Drug Profile
tarextumab - Drug Profile
temozolomide - Drug Profile
TF-2 - Drug Profile
topotecan hydrochloride liposomal - Drug Profile
Tozaride - Drug Profile
TRBS-07 - Drug Profile
Vaccine for Small Cell Lung Cancer - Drug Profile
vandetanib - Drug Profile
veliparib - Drug Profile
vinorelbine tartrate liposomal - Drug Profile
vorinostat - Drug Profile
VX-970 - Drug Profile
X-396 - Drug Profile
XMT-1001 - Drug Profile
ZS-05 - Drug Profile
Small-Cell Lung Cancer - Recent Pipeline Updates
Small-Cell Lung Cancer - Dormant Projects
Small-Cell Lung Cancer - Discontinued Products
Small-Cell Lung Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H1 2015
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2015
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2015
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Array BioPharma Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2015
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2015
Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Blend Therapeutics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015
Small-Cell Lung Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2015
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2015
Small-Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2015
Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015
Small-Cell Lung Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2015
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2015
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2015
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2015
Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2015
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2015
Small-Cell Lung Cancer - Pipeline by Neotropix, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2015
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2015
Small-Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2015
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2015
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015
Small-Cell Lung Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Small-Cell Lung Cancer - Dormant Projects, H1 2015
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2015
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2015
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2015
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2015
Small-Cell Lung Cancer - Discontinued Products, H1 2015
Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H1 2015
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report